Welcome to our dedicated page for Elevation Oncolo news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncolo stock.
Elevation Oncology, Inc. (formerly Nasdaq: ELEV) has generated a range of news focused on its efforts to develop selective cancer therapies for solid tumors with significant unmet medical needs and on its subsequent corporate transformation. Company press releases highlight its concentration on antibody-drug conjugate (ADC) programs targeting Claudin 18.2 and HER3, as well as key corporate and transactional milestones.
Earlier news coverage centers on Elevation Oncology’s pipeline updates and scientific progress. The company reported clinical and preclinical developments for EO-3021, a Claudin 18.2 ADC evaluated in a Phase 1 trial for advanced gastric and gastroesophageal junction adenocarcinoma, including monotherapy and combination cohorts with ramucirumab and dostarlimab. It also announced preclinical proof-of-concept data and development plans for EO-1022, a HER3-targeting ADC designed for HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer, and described licensing of a site-specific ADC technology platform from Synaffix B.V.
Subsequent news includes strategic decisions and corporate restructuring. On March 20, 2025, Elevation Oncology disclosed that it would discontinue development of EO-3021 after evaluating updated Phase 1 data, and that it would implement a significant workforce reduction while focusing on EO-1022 and evaluating strategic options. Financial results releases have provided context on research and development spending, general and administrative expenses, restructuring charges, and cash runway expectations, as reported by the company.
A major news development occurred on June 9, 2025, when Elevation Oncology announced a definitive merger agreement under which Concentra Biosciences, LLC would acquire the company through a tender offer and subsequent merger, with shareholders receiving cash consideration and a non-tradeable contingent value right. A later Form 8-K dated July 23, 2025 confirms completion of the tender offer and merger, after which Elevation Oncology became a wholly owned subsidiary of Concentra and moved to delist and deregister its common stock.
Readers following historical ELEV news can review these updates to understand Elevation Oncology’s scientific focus on ADCs, its program-level decisions, financial disclosures, participation in scientific and investor conferences, and the steps that led to its acquisition and transition away from public trading.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Elevation Oncology has announced the selection of an abstract for SYSA1801 (EO-3021) Phase 1 clinical data for presentation at the ASCO 2023 Annual Meeting in Chicago, from June 2-6, 2023. The ongoing Phase 1 study is focused on evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors, conducted in partnership with CSPC Pharmaceutical Group in China. Elevation plans to advance its clinical trial for EO-3021 in the U.S. in the second half of 2023. EO-3021 targets Claudin 18.2, a significant unmet need in oncology, particularly for gastric and pancreatic cancers, with no existing approved therapies. The U.S. FDA has cleared an Investigational New Drug application for EO-3021.
Elevation Oncology (Nasdaq: ELEV) recently presented preclinical data for its lead candidate EO-3021 targeting Claudin 18.2 at the AACR Annual Meeting 2023. The antibody-drug conjugate displayed anti-tumor efficacy in various cancers like gastric and pancreatic in preclinical models. Notably, EO-3021 achieved a confirmed partial response in a patient with metastatic gastric cancer during a Phase 1 trial in China, showing a 66.7% tumor reduction over approximately 11 months of treatment. The company plans to initiate a US Phase 1 clinical trial in the latter half of 2023, further advancing EO-3021's development aimed at addressing significant unmet medical needs in oncology.
Elevation Oncology (Nasdaq: ELEV) has announced it will present preclinical proof-of-concept data for its drug candidate EO-3021 at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19, 2023. The oral presentation is scheduled for April 17, showcasing EO-3021, an antibody-drug conjugate targeting Claudin 18.2, which may become a leading treatment for solid tumors. Additionally, two posters will detail findings from a Phase 2 CRESTONE study on NRG1 fusions. The company aims to initiate a Phase 1 clinical trial for EO-3021 in the U.S. in the latter half of 2023.